← back to search

Simon Kirste

University of Freiburg · DE
Area of research
Pulmonary and Respiratory Medicine · Radiation
Research interest
Research interests include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Advanced Radiotherapy Techniques, and Hepatocellular Carcinoma Treatment and Prognosis.
h-index
25
citations
2,078
works
129
NIH funding
primary concept
email

Recent publications

Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01)
Radiotherapy and Oncology 2025cited by 7position: middledoi
The role of ALBI score in patients treated with stereotactic body radiotherapy for locally advanced primary liver tumors: a pooled analysis of two prospective studies
Frontiers in Oncology 2024cited by 4position: middledoi
Outcome of intraoperative brachytherapy as a salvage treatment for locally recurrent rectal cancer
Strahlentherapie und Onkologie 2024cited by 1position: middledoi
Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy
European Journal of Nuclear Medicine and Molecular Imaging 2023cited by 20position: middledoi
Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: Multi-center analysis on the value of standard treatment in the elderly
Frontiers in Oncology 2023cited by 18position: middledoi
Toxicity and Patient Reported Quality of Life after PSMA-PET and mpMRT-Based Focal Dose Escalated Definitive Radiotherapy in Prostate Cancer Patients: 2-Year Follow-Up of the HypoFocal Phase II Trial
International Journal of Radiation Oncology*Biology*Physics 2023cited by 1position: middledoi
Analysis of MRI and CT-based radiomics features for personalized treatment in locally advanced rectal cancer and external validation of published radiomics models
Scientific Reports 2022cited by 41position: middledoi
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy
International Journal of Radiation Oncology*Biology*Physics 2022cited by 31position: middledoi
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis
European Journal of Nuclear Medicine and Molecular Imaging 2022cited by 30position: middledoi
Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus
International Journal of Radiation Oncology*Biology*Physics 2022cited by 25position: middledoi
Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel–Lindau Disease—Results of a Prospective Trial
Cancers 2022cited by 15position: firstdoi
Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited
Cancers 2022cited by 11position: middledoi
Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer
Frontiers in Oncology 2022cited by 10position: middledoi
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
JAMA Oncology 2021cited by 345position: middledoi
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
Cancers 2021cited by 47position: middledoi
Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
Frontiers in Oncology 2021cited by 25position: middledoi
Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
Frontiers in Oncology 2021cited by 15position: firstdoi
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
BMC Cancer 2020cited by 25position: middledoi
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study
European Journal of Nuclear Medicine and Molecular Imaging 2020cited by 23position: middledoi
Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial
European Journal of Cancer 2020cited by 19position: middledoi
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy
European Journal of Nuclear Medicine and Molecular Imaging 2020cited by 16position: middledoi
Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
Cancers 2020cited by 16position: middledoi
Predicting Biochemical Failure in Irradiated Patients With Prostate Cancer by Tumour Volume Measured by Multiparametric MRI
In Vivo 2020cited by 1position: middledoi
Stereotactic Body Radiotherapy vs Transarterial Chemoembolization In Locally Advanced Hepatocellular Carcinoma (HERACLES: Hepatocellular Carcinoma Stereotactic Radiotherapy Clinical Efficacy Study)
International Journal of Radiation Oncology*Biology*Physics 2020cited by 0position: middledoi
Prostate-specific Membrane Antigen Positron Emission Tomography–detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation
European Urology Focus 2019cited by 42position: middledoi
Retroperitoneal soft tissue sarcoma: low-dose neoadjuvant radiation therapy followed by surgery with or without intraoperative radiotherapy and adjuvant radiation therapy
Strahlentherapie und Onkologie 2019cited by 6position: firstdoi
Outcome After PSMA PET/CT–Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis
Journal of Nuclear Medicine 2018cited by 89position: middledoi
The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer
Radiation Oncology 2018cited by 33position: middledoi
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
BMC Cancer 2018cited by 33position: middledoi
Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection
Radiation Oncology 2018cited by 30position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Anca‐Ligia Grosu · German Marine Research Consortium34 papers (2015–2025)Constantinos Zamboglou · University of Freiburg14 papers (2015–2025)Eleni Gkika · Deutschen Konsortium für Translationale Krebsforschung14 papers (2017–2024)Thomas Brunner · University of Konstanz12 papers (2017–2021)Sonja Adebahr · Heidelberg University10 papers (2017–2025)Ursula Nestle · Heidelberg University10 papers (2017–2018)Michael Mix · University Medical Center Freiburg9 papers (2017–2025)Dimos Baltas · University of Freiburg8 papers (2017–2025) · 8 papers (2017–2024)Matthias Gückenberger · Stadtspital Waid7 papers (2017–2021)Peter Bartenstein · LMU Klinikum7 papers (2018–2021)Claus Belka · Cancer Research Center7 papers (2018–2021)Nina-Sophie Schmidt-Hegemann · LMU Klinikum7 papers (2018–2021)Dominik Bettinger · Charité - Universitätsmedizin Berlin7 papers (2017–2021)Robert Thimme · Heinrich Heine University Düsseldorf7 papers (2017–2024) · 7 papers (2017–2021)Michael Schultheiß · Johannes Gutenberg University Mainz7 papers (2017–2021)Stephanie E. Combs · Brooke Army Medical Center6 papers (2019–2022)Philipp T. Meyer · University Medical Center Freiburg6 papers (2015–2020)Matthias Eiber · Comprehensive Cancer Center Erlangen6 papers (2018–2021)